ES2306461T3 - Metodos para preparar inhibidores de la proteasa del vih e intermedios para su preparacion. - Google Patents

Metodos para preparar inhibidores de la proteasa del vih e intermedios para su preparacion. Download PDF

Info

Publication number
ES2306461T3
ES2306461T3 ES97940770T ES97940770T ES2306461T3 ES 2306461 T3 ES2306461 T3 ES 2306461T3 ES 97940770 T ES97940770 T ES 97940770T ES 97940770 T ES97940770 T ES 97940770T ES 2306461 T3 ES2306461 T3 ES 2306461T3
Authority
ES
Spain
Prior art keywords
compound
formula
baselineskip
alkyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97940770T
Other languages
English (en)
Spanish (es)
Inventor
Srinivasan Babu
Bennett C. Borer
Travis P. Remarchuk
Robert J. Szendroi
Kathleen R. Whitten
Juliette K. Busse
Kim F. Albizati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Original Assignee
Japan Tobacco Inc
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Agouron Pharmaceuticals LLC filed Critical Japan Tobacco Inc
Application granted granted Critical
Publication of ES2306461T3 publication Critical patent/ES2306461T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/22Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES97940770T 1996-09-05 1997-09-04 Metodos para preparar inhibidores de la proteasa del vih e intermedios para su preparacion. Expired - Lifetime ES2306461T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/708,607 US5705647A (en) 1996-09-05 1996-09-05 Intermediates for making HIV-protease inhibitors
US708607 1996-09-05

Publications (1)

Publication Number Publication Date
ES2306461T3 true ES2306461T3 (es) 2008-11-01

Family

ID=24846475

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97940770T Expired - Lifetime ES2306461T3 (es) 1996-09-05 1997-09-04 Metodos para preparar inhibidores de la proteasa del vih e intermedios para su preparacion.

Country Status (16)

Country Link
US (1) US5705647A (cg-RX-API-DMAC7.html)
EP (1) EP0931071B1 (cg-RX-API-DMAC7.html)
JP (2) JP2001501183A (cg-RX-API-DMAC7.html)
AR (1) AR009532A1 (cg-RX-API-DMAC7.html)
AT (1) ATE397591T1 (cg-RX-API-DMAC7.html)
AU (1) AU4247097A (cg-RX-API-DMAC7.html)
CA (1) CA2264725A1 (cg-RX-API-DMAC7.html)
CO (1) CO4900044A1 (cg-RX-API-DMAC7.html)
DE (1) DE69738751D1 (cg-RX-API-DMAC7.html)
ES (1) ES2306461T3 (cg-RX-API-DMAC7.html)
ID (1) ID17012A (cg-RX-API-DMAC7.html)
IN (1) IN183739B (cg-RX-API-DMAC7.html)
MY (1) MY132553A (cg-RX-API-DMAC7.html)
UY (1) UY24697A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998009952A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA977868B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962725A (en) * 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) * 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE234288T1 (de) * 1997-04-10 2003-03-15 Hoffmann La Roche Verfahren zur herstellung eines buthylthuio- isochinolinderivates und zwischenprodukte dafür
US6130348A (en) * 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
WO1999048371A1 (en) * 1998-03-27 1999-09-30 The Regents Of The University Of California Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
US20050049242A1 (en) * 2000-12-21 2005-03-03 W. Edward Robinson Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CA2456229A1 (en) * 2001-08-03 2003-02-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
CN1819993A (zh) * 2003-05-08 2006-08-16 美国辉瑞有限公司 用于合成hiv-蛋白酶抑制剂的中间体及其制备方法
US9227950B2 (en) 2010-10-22 2016-01-05 Mitsui Chemicals, Inc. Cyclic sulfate compound, non-aqueous electrolyte solution containing same, and lithium secondary battery

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
IL100899A (en) * 1991-02-08 1997-06-10 Sankyo Co Beta-amino-alpha- hydroxycarboxylic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5256783A (en) * 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
DK0560268T3 (da) * 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
EP1447398A1 (en) * 1992-05-21 2004-08-18 Monsanto Company Retroviral protease inhibitors
DE69332002T2 (de) * 1992-08-25 2002-12-19 Monsanto Co Hydroxyethylaminosulfonamide verwendbar als Inhibitoren retroviraler Proteasen
CA2142998C (en) * 1992-08-25 2008-01-29 Michael L. Vazquez N-(alkanoylamino-2-hydroxypropyl)-sulfonamides useful as retroviral protease inhibitors
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
IN183739B (cg-RX-API-DMAC7.html) 2000-04-01
CO4900044A1 (es) 2000-03-27
JP2001501183A (ja) 2001-01-30
ATE397591T1 (de) 2008-06-15
WO1998009952A1 (en) 1998-03-12
EP0931071A1 (en) 1999-07-28
JP2009040788A (ja) 2009-02-26
US5705647A (en) 1998-01-06
AR009532A1 (es) 2000-04-26
ZA977868B (en) 1998-03-30
MY132553A (en) 2007-10-31
EP0931071B1 (en) 2008-06-04
DE69738751D1 (de) 2008-07-17
UY24697A1 (es) 1997-10-21
ID17012A (id) 1997-11-27
AU4247097A (en) 1998-03-26
CA2264725A1 (en) 1998-03-12

Similar Documents

Publication Publication Date Title
ES2306461T3 (es) Metodos para preparar inhibidores de la proteasa del vih e intermedios para su preparacion.
ES2332037T3 (es) Procedimiento para la produccion de 1,1,1-trifluoro-3-buten-2-ona sustituidos.
ES2562080T3 (es) Proceso y compuestos intermedios para preparar inhibidores de integrasa
ES2347987T3 (es) Proceso para preparar (s)-4-fluorometil-dihidro-furan-2-ona.
ES2237970T3 (es) Produccion de 2-amino-2-(2-(4-alquil c2-20-fenil)etil)propano-1,3-dioles.
ES2393009T3 (es) Derivados de indazolil sulfonamida útiles como moduladores de glucocorticoides
ES2847239T3 (es) Procedimientos para la preparación de 4-alcoxi-3-(acil o alquil)oxipicolinamidas
ES2364502T3 (es) Alquilación asimétrica de carbonilo.
ES2318852T3 (es) Procedimiento para producir derivados de amida y compuestos intermedios.
ES2337998T3 (es) Producto intermedio quimico.
ES2298384T3 (es) Procedimiento para la produccion del derivado de piperidina fexofenadina.
US6316625B1 (en) Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
WO2022006427A1 (en) Manufacturing process for 3,5-dichloropicolinonitrile for synthesis of vadadustat
ES2296177T3 (es) Procedimiento para preparar derivados de 2-oxo-1-pirrolidina por alilacion intramolecular.
ES2290769T3 (es) Sintesis estereoselectiva de ciertos alcoholes substituidos con trifluormetilo.
ES2282365T3 (es) Metodo para la preparacion de citalopram.
ES2467677T3 (es) Procedimiento para la preparación de (3S,4S)-4-((R)-2-(benciloxi)tridecil)-3-hexil-2-oxetanona y un nuevo intermediario utilizado para el mismo
ES2234797T3 (es) Procedimiento para la preparacion de citalopram partiendo de 5-formilftalida.
ES2335488T3 (es) Alquilacion estereoselectiva de piperazinas quirales 2-metil-4-protegidas.
ES2227481T3 (es) Derivados benzoaxatiepinas y su utilizacion como medicamentos.
ES2346986T3 (es) Proceso de sintesis diastereoselectiva con 6-bromo-4-(3-clorofenil)-2-methoxi-quinolina.
US6084107A (en) Intermediates for making HIV-protease inhibitors
ES2308486T3 (es) Proceso de sintesis diastereoselectiva para la preparacion de compuestos de imidazol.
CA2549271A1 (en) Methods of making hiv-protease inhibitors and intermediates for making them
PT1542968E (pt) Processo para preparar intermediários